Medpace Holdings, Inc. — Q2 2022 Form 10-Q
Reporting period: Three and six months ended June 30, 2022. Unaudited results; amounts below are in U.S. dollars unless noted. Medpace is a global clinical research organization providing outsourced clinical development services to pharmaceutical, biotechnology, and medical-device companies.
Financial performance
| Metric | Q2 2022 | Q2 2021 | First half 2022 | First half 2021 |
|---|---|---|---|---|
| Revenue | $351.2 million | $278.3 million | $682.2 million | $538.3 million |
| Operating income | $60.2 million | $42.4 million | $124.4 million | $90.0 million |
| Net income | $49.4 million | $39.9 million | $110.7 million | $83.2 million |
| Diluted EPS | $1.46 | $1.06 | $3.16 | $2.20 |
| Operating margin | 17.1% | 15.3% | 18.2% | 16.7% |
| Net margin | 14.1% | 14.4% | 16.2% | 15.5% |
Q2 revenue increased 26.2% year over year and first-half revenue increased 26.7%. Management attributed growth primarily to Oncology, Metabolic, Cardiology, and Central Nervous System services. Operating income grew faster than revenue, while Q2 net margin was lower, reflecting a higher income-tax provision.
- Costs: Q2 direct costs rose 23.9% to $252.2 million, including higher personnel costs and reimbursed project expenses. SG&A rose 23.1% to $33.2 million, primarily due to personnel costs.
- Cash flow: First-half operating cash flow was $142.9 million, versus $120.1 million in 2021. Investing cash outflow was $22.3 million, mainly capital expenditures of $20.5 million.
- Liquidity and debt: Cash was $42.6 million at June 30, down from $461.3 million at year-end 2021. Debt under the revolving facility was $249.7 million; the filing reported only $0.1 million available to borrow. The debt was classified as short-term and principal was due in 2023. Facility interest was based on SOFR plus the benchmark replacement adjustment and 1.00%.
- Balance sheet: Total assets were $1.315 billion and total liabilities were $1.032 billion. Current liabilities of $879.0 million exceeded current assets of $328.9 million; advanced billings accounted for $401.4 million of current liabilities.
Material changes and notable items
- Medpace repurchased 5.46 million shares for approximately $800.5 million in the first half, including $374.6 million in Q2. It had completed all authorized repurchases by June 30. Financing cash outflow was $535.5 million, with repurchases the principal use of funds, partly funded by $299.2 million of revolving-facility proceeds.
- Shareholders’ equity declined to $283.3 million from $952.9 million at year-end, and retained earnings became an accumulated deficit of $446.1 million. The filing attributes the change principally to share repurchases and their accounting treatment.
- First-half net new business awards were $873.6 million, compared with $743.7 million in the prior-year period. Backlog was $2.168 billion, up 24.4% from June 2021; the company estimated $1.12–$1.14 billion would convert to revenue over the next 12 months. Backlog is not a guarantee of future revenue and can change with cancellations, scope, timing, and foreign exchange.
- The filing also reported approximately $2.5 billion of remaining performance obligations for active projects; this measure is distinct from reported backlog.
- The effective tax rate was 20.4% for Q2 and 13.1% for the first half, compared with 6.4% and 8.7%, respectively, in 2021. Management cited higher pretax income and fewer excess share-based compensation tax benefits as factors in the Q2 increase.
Outlook, risks, and contingencies
The filing gives no specific revenue or earnings guidance. Management described continued COVID-19 effects on site access, patient enrollment, and trial start-up, while expecting these impacts to be temporary; it said the financial effect could not be reasonably estimated. It also identified inflation and competitive pricing as potential operating-margin pressures, alongside international, foreign-exchange, and Russia-Ukraine-related risks. The company noted that customer trial cancellations and funding constraints—particularly among smaller clients—could affect activity and backlog conversion.
Legal proceedings in the ordinary course were described as immaterial, although the company acknowledged a reasonable possibility that losses could exceed amounts already recognized. Purchase commitments for project supplies totaled $14.7 million. Related-party arrangements include clinical-service revenue, leases with entities owned by the CEO and family members, and executive travel services; the filing discloses these transactions and related balances.
Key facts for investors to verify
- Whether backlog and awards convert to revenue on the expected timeline, and how cancellations and foreign-exchange movements evolve.
- Cash generation, debt repayment capacity, and the effect of the completed buyback on liquidity and financial flexibility.
- Whether operating-margin gains persist as staffing, reimbursable project costs, inflation, and competitive pricing change.
- How tax expense compares with the unusually low prior-year rates and whether share-based compensation tax benefits continue.
- The extent of ongoing trial disruption, customer funding risk, international exposure, and related-party transaction terms.